Teva’s biosimilar, PONLIMSI™, is now FDA-approved across all indications of the reference product, Prolia ® (denosumab), to treat a variety of ...

The receptor activator of nuclear factor kappa B ligand (RANKL) signaling pathway is a key mediator of bone remodeling and so represents an attractive target for the development of novel osteoporosis ...

复宏汉霖(2696.HK)与Organon(OGN.US)今日联合宣布，欧盟委员会已批准地舒单抗注射液(60 mg/mL)BILDYOS®(denosumab)和地舒单抗注射液(120mg ...

EC approval based on robust development program confirming that biosimilar matches reference medicine in terms of safety, efficacy and quality Approved for treatment of cancer-related bone disease and ...

Fresenius Kabi continues the expansion of its biosimilars portfolio in the U.S. with the introduction of Conexxence (denosumab-bnht) and Bomyntra® (denosumab-bnht) in the United States. Bomyntra is ...

Please provide your email address to receive an email when new articles are posted on . Cancer treatment-induced bone loss and skeletal-related events resulting from bone metastases cause significant ...

Please provide your email address to receive an email when new articles are posted on . Denosumab is associated with a greater increase in lumbar spine bone mineral density at 12 months compared with ...

Patients with rheumatic diseases who are treated with denosumab (Prolia®, Xgeva®) either alone, or in combination with either biologic or non-biologic disease-modifying antirheumatic drugs (DMARDs), ...

Compared with oral bisphosphonates, denosumab reduced fracture risk among treatment-experienced postmenopausal women with osteoporosis. Treatment with denosumab vs oral bisphosphonates is associated ...

Symptom burden in cancer survivors 1 year after diagnosis: A report from the American Cancer Society's studies of cancer survivors. Background: Bone metastases from solid tumors increase risk for ...